Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Israeli Controlled Drug Release Company Polypid Raises $50 Million
Error: Contact form not found.
by CTech Staff
A doctor performing a botox injection. Photo: Dr. Braun via Wikicommons.
CTech – Israel-based biotech company Polypid has closed a $50 million funding round led by unspecified institutional shareholders, the company announced Monday. Polypid intends to use the proceeds to advance the development of its pipeline and conduct two phase 3 pivotal registration trials of its flagship product.
Founded in 2008 and based in central Israeli town Petah Tikva, clinical-stage Polypid develops encapsulating drug delivery technology that enables extended and localized release of tricky compounds like those sensitive to heat or pH levels, or drugs that are toxic in large doses. The company raised $15 million in November according to a pre-money valuation of $180 million. In March, the company postponed its planned initial public offering on Nasdaq, through which it intended to raise $75 million.
